<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02889510</url>
  </required_header>
  <id_info>
    <org_study_id>LIRALUNG</org_study_id>
    <nct_id>NCT02889510</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Multicentre Randomized Double Blind, Crossover, Placebo Controlled Clinical Trial to Evaluate the Effect of Liraglutide on Lung Function in Patients With Type 2 Diabetes Mellitus (LIRALUNG Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lecube, Albert, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dynamic Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lecube, Albert, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes (T2DM) is related to reduced pulmonary function. As experimental studies with&#xD;
      glucagon-like peptide 1 (GLP-1) have shown an increase in pulmonary surfactant secretion, and&#xD;
      the GLP-1 receptor has been found in significant amounts in the lung, it could be&#xD;
      hypothesized that the treatment with liraglutide (a GL-1 agonist) will improve this reduced&#xD;
      pulmonary function&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is growing evidence to suggest an association between type 2 diabetes and impaired&#xD;
      pulmonary function. In this regard, several cross-sectional studies have appeared showing&#xD;
      decreased indices of forced expiration, lung volume and diffusion capacity as the main lung&#xD;
      dysfunctions detected in type 2 diabetic populations. In fact, diabetes is frequently&#xD;
      co-morbid with chronic obstructive pulmonary disease, and data from the Atherosclerosis Risk&#xD;
      in Communities Study showed a faster pulmonary function decline in type 2 diabetic patients&#xD;
      than in other participants. This is important because the reduction of FEV1 has been&#xD;
      demonstrated an independent cause of mortality in diabetic patients.&#xD;
&#xD;
      Interestingly, lung function measures start to decrease several years before the diagnosis of&#xD;
      diabetes. In this regard an investigation found that insulin resistance is an independent&#xD;
      determinant of pulmonary function in non-diabetic morbidly obese women. In addition, the&#xD;
      results suggest that the metabolic pathways related to insulin resistance are crucial in&#xD;
      initiating lung abnormalities in type 2 diabetic patients.&#xD;
&#xD;
      The reasons for the association between respiratory disease and diabetes are unclear.&#xD;
      However, the relationship between type 2 diabetes and muscle strength, the impairment in lung&#xD;
      elastic properties, and the presence of a low-grade chronic inflammation state are involved.&#xD;
      In supporting these findings, thickening of the alveolar epithelia and pulmonary capillary&#xD;
      basal lamina, fibrosis, centrilobular emphysema, and pulmonary microangiopathy have been&#xD;
      detected in autopsies of diabetic patients. In addition, defects in the bronchiolar&#xD;
      surfactant layer, which is involved in maintaining airway stability and diameter, may also be&#xD;
      considered a contributing factor to the impairment of airway calibre regulation in diabetic&#xD;
      patients. When the alveolocapillary barrier is damaged, surfactant proteins leak into the&#xD;
      bloodstream. A recent population-based random sample study has described how increased&#xD;
      circulating levels of surfactant protein A, the major surfactant-associated protein, were&#xD;
      associated with altered glucose tolerance and insulin resistance. Therefore, surfactant&#xD;
      defects in diabetic individuals may also lead to an increase in airway resistance and to a&#xD;
      reduction in ventilatory patterns as observed in our studies. In addition, as experimental&#xD;
      studies have shown that glucagon-like peptide 1 plays a role in the stimulation of surfactant&#xD;
      production, its underlying deficit in type 2 diabetes could also enhance the airway&#xD;
      resistance observed in these patients. However, the beneficial effects on pulmonary function&#xD;
      using incretin-based therapies remain to be elucidated.&#xD;
&#xD;
      Clinical trial study hypothesis is that treatment with an incretin mimetic such as&#xD;
      liraglutide may ameliorate lung function parameters in type 2 diabetics patients,&#xD;
      independently of weight reduction. This hypothesis is based on the following factors:&#xD;
&#xD;
        1. - There is growing evidence to suggest an association between type 2 diabetes and&#xD;
           impaired pulmonary function.&#xD;
&#xD;
        2. - In patients with type 2 diabetes, the incretin effect is severely reduced or absent,&#xD;
           contributing to the reduced lung function parameters observed in type 2 diabetic&#xD;
           patients.&#xD;
&#xD;
        3. - GLP-1 stimulates surfactant production in &quot;in vitro&quot; studies and, in consequence, the&#xD;
           increase in surfactant production induced by liraglutide could be the main factor&#xD;
           involved in the respiratory improvement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2016</start_date>
  <completion_date type="Actual">December 16, 2019</completion_date>
  <primary_completion_date type="Actual">November 18, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by forced expiratory volume in 1 second (FEV1).&#xD;
Mean difference between 7 weeks after treatment visit and baseline visit is registered.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline on Measurements of Respiratory Function Defined by Forced Vital Capacity (FVC)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by forced vital capacity (FVC).&#xD;
Mean difference between 7 weeks after treatment visit and baseline visit is registered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Serum Levels of Surfactant A and D Protein</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline in serum levels of surfactant A and D protein. Values for surfactant A or D protein after 7 treatment weeks (liraglutide or placebo) are registered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline on Measurements of Respiratory Function Defined by Maximum Mid-expiratory Flow (FEF25-75)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by Maximum mid-expiratory flow (FEF25-75).&#xD;
Mean difference between 7 weeks after treatment visit and baseline visit is registered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second/Forced Vital Capacity (FEV1/FVC)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC).&#xD;
Mean difference between 7 weeks after treatment visit and baseline visit is registered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline on Measurements of Respiratory Function Defined by Residual Volume (RV)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by residual volume (RV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline on Measurements of Respiratory Function Defined by Total Lung Capacity (TLC)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by Total lung capacity (TLC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline on Measurements of Respiratory Function Defined by Residual Functional Capacity (RFC)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Changes from baseline on measurements of respiratory function defined by Residual functional capacity (RFC) are registered.&#xD;
However, this parameter was not determined in patients due to an error in the programm used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>liraglutide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7-week subcutaneous liraglutide treatment once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>7-week subcutaneous placebo treatment once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>7-week subcutaneous liraglutide once daily</description>
    <arm_group_label>liraglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>7-week subcutaneous placebo once daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Subjects between 40 and 65 years old. Diagnosis of type 2 diabetes mellitus with more&#xD;
             than 5 years of evolution of disease.&#xD;
&#xD;
          -  Metformin (alone or in combination with sulfonylurea and / or insulin and / or&#xD;
             thiazolidinediones) at a stable dose for at least the past 3 months.&#xD;
&#xD;
          -  HbA1c ≥ 7,0 y ≤ 9,0 %.&#xD;
&#xD;
          -  BMI between 30 and 40 kg / m2.&#xD;
&#xD;
          -  No pulmonary disease (COPD, asthma, fibrosis, etc) known.&#xD;
&#xD;
          -  Baseline FEV1 decline of equal or greater than 10% in the percentage of the&#xD;
             theoretical value.&#xD;
&#xD;
          -  Chest radiography without significant changes in the lung parenchyma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Treatment with inhibitors of dipeptidyl peptidase 4 glitazones and / or&#xD;
&#xD;
          -  SGLT2 inhibitors.&#xD;
&#xD;
          -  Active and former smokers for less than five years ago smoking.&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease.&#xD;
&#xD;
          -  Respiratory sleep disorders that require treatment with continuous positive pressure&#xD;
             in the airway.&#xD;
&#xD;
          -  Asthma treatment with bronchodilators.&#xD;
&#xD;
          -  Previous bariatric surgery.&#xD;
&#xD;
          -  Cardiovascular disease, heart failure and / or stroke.&#xD;
&#xD;
          -  Pathology of the chest wall.&#xD;
&#xD;
          -  Serum creatinine&gt; 1.7 mg / dl.&#xD;
&#xD;
          -  Abnormal results in liver function test (Alanine transaminase/ Aspartate&#xD;
             Aminotransferase greater than twice the upper limit of normal).&#xD;
&#xD;
          -  History of acute or chronic pancreatitis.&#xD;
&#xD;
          -  Personal or family history of medullary thyroid cancer or Multiple&#xD;
&#xD;
          -  Endocrine Neoplasia (MEN ) type 2.&#xD;
&#xD;
          -  Active neoplasms or neoplastic patients considered disease-free history from less than&#xD;
             5 years ago.&#xD;
&#xD;
          -  Women of childbearing age who are pregnant (positive pregnancy test within 14 days&#xD;
             before the start of treatment) or intend to get pregnant.&#xD;
&#xD;
          -  Lactating women.&#xD;
&#xD;
          -  Women of childbearing potential not using adequate contraception (such as oral&#xD;
             contraceptives, intrauterine device or barrier method of birth control along with&#xD;
             spermicide or surgical sterilization) or unwilling to use during the study (as&#xD;
             required by local laws or practices).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Lecube, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitari Arnau de Vilanova de Lleida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d´Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Davis TM, Knuiman M, Kendall P, Vu H, Davis WA. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract. 2000 Oct;50(2):153-9.</citation>
    <PMID>10960726</PMID>
  </reference>
  <reference>
    <citation>Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Cox CE, Selvin E, Brancati FL. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2008 Apr;31(4):741-6. Epub 2007 Dec 4.</citation>
    <PMID>18056886</PMID>
  </reference>
  <reference>
    <citation>Vara E, Arias-Díaz J, Garcia C, Balibrea JL, Blázquez E. Glucagon-like peptide-1(7-36) amide stimulates surfactant secretion in human type II pneumocytes. Am J Respir Crit Care Med. 2001 Mar;163(4):840-6.</citation>
    <PMID>11282754</PMID>
  </reference>
  <reference>
    <citation>Lecube A, Sampol G, Muñoz X, Lloberes P, Hernández C, Simó R. Insulin resistance is related to impaired lung function in morbidly obese women: a case-control study. Diabetes Metab Res Rev. 2010 Nov;26(8):639-45. doi: 10.1002/dmrr.1131. Epub 2010 Sep 29.</citation>
    <PMID>20882512</PMID>
  </reference>
  <reference>
    <citation>Lecube A, Sampol G, Muñoz X, Hernández C, Mesa J, Simó R. Type 2 diabetes impairs pulmonary function in morbidly obese women: a case-control study. Diabetologia. 2010 Jun;53(6):1210-6. doi: 10.1007/s00125-010-1700-5. Epub 2010 Mar 9.</citation>
    <PMID>20217039</PMID>
  </reference>
  <reference>
    <citation>Lecube A, Sampol G, Lloberes P, Romero O, Mesa J, Hernández C, Simó R. Diabetes is an independent risk factor for severe nocturnal hypoxemia in obese patients. A case-control study. PLoS One. 2009;4(3):e4692. doi: 10.1371/journal.pone.0004692. Epub 2009 Mar 5.</citation>
    <PMID>19262746</PMID>
  </reference>
  <reference>
    <citation>Fernández-Real JM, Chico B, Shiratori M, Nara Y, Takahashi H, Ricart W. Circulating surfactant protein A (SP-A), a marker of lung injury, is associated with insulin resistance. Diabetes Care. 2008 May;31(5):958-63. doi: 10.2337/dc07-2173. Epub 2008 Feb 19.</citation>
    <PMID>18285549</PMID>
  </reference>
  <reference>
    <citation>Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008 Oct;32(4):962-9. doi: 10.1183/09031936.00012408. Epub 2008 Jun 25.</citation>
    <PMID>18579551</PMID>
  </reference>
  <reference>
    <citation>Davis WA, Knuiman M, Kendall P, Grange V, Davis TM; Fremantle Diabetes Study. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2004 Mar;27(3):752-7.</citation>
    <PMID>14988297</PMID>
  </reference>
  <reference>
    <citation>Nicolaie T, Zăvoianu C, Nuţă P. Pulmonary involvement in diabetes mellitus. Rom J Intern Med. 2003;41(4):365-74. Review.</citation>
    <PMID>15526520</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2016</study_first_posted>
  <results_first_submitted>December 21, 2020</results_first_submitted>
  <results_first_submitted_qc>February 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2021</results_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>liraglutide</keyword>
  <keyword>lung function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02889510/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>It is a cross-over study so patients are in both arms if they complete all the study. The order of the treatment received depends on the group assigned:&#xD;
A= treatment with subcutaneus liraglutide for 7 weeks once daily followed by treatment with subcutaneus placebo for 7 weeks B= treatment with subcutaneus placebo for 7 weeks once daily followed by treatment with subcutaneus liraglutide for 7 weeks&#xD;
76 participants were enrolled in the study but only 72 started the treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Liraglutide First, Then Placebo</title>
          <description>treatment with subcutaneus liraglutide for 7 weeks once daily followed by treatment with subcutaneus placebo for 7 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Liraglutide</title>
          <description>treatment with subcutaneus placebo for 7 weeks once daily followed by treatment with subcutaneus liraglutide for 7 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Never smokers</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <population>Two arms.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Liraglutide first, then placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.7" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo first,then liraglutide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <population>Two arms.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Liraglutide first, then placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146.9" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo first,then liraglutide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145.2" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose</title>
          <population>Two arms.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Liraglutide first, then placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.0" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo first, then liraglutide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.9" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycated hemoglobin (HbA1c)</title>
          <population>Two arms.</population>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Liraglutide first, then placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo first, then liraglutide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycated hemoglobin (HbA1c)</title>
          <population>Two arms.</population>
          <units>mmol/mol</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Liraglutide first, then placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo first, then liraglutide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced expiratory volume in 1s (FEV1)</title>
          <population>Two arms.</population>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Liraglutide first, then placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.1" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo first, then liraglutide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.8" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced vital capacity (FVC)</title>
          <population>Two arms.</population>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Liraglutide first, then placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.9" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo first, then liraglutide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.6" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum mid-expiratory flow (FEF25-75)</title>
          <population>Two arms.</population>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Liraglutide first, then placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.2" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo first, then liraglutide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.1" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peak expiratory flow (PEF)</title>
          <population>Two arms.</population>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Liraglutide first, then placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.7" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo first, then liraglutide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.7" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1/FVC</title>
          <population>Two arms.</population>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Liraglutide first, then placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.6" lower_limit="77.1" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo first, then liraglutide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.3" lower_limit="77.6" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non obstructive ventilatory defect (VD)</title>
          <population>Two arms.</population>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Liraglutide first, then placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo first, then liraglutide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surfactant A protein</title>
          <population>Two arms.</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Liraglutide first, then placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" lower_limit="19.4" upper_limit="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo first, then liraglutide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.2" lower_limit="20.5" upper_limit="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surfactant D protein</title>
          <population>Two arms</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Liraglutide first, then placebo</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196.5" lower_limit="128.3" upper_limit="271.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Placebo first, then liraglutide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184.2" lower_limit="118.3" upper_limit="287.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Changes from baseline on measurements of respiratory function defined by forced expiratory volume in 1 second (FEV1).&#xD;
Mean difference between 7 weeks after treatment visit and baseline visit is registered.</description>
        <time_frame>7 weeks</time_frame>
        <population>59 patients ended the period of 7 weeks of liraglutide treatment (A group + B group) but only 50 have this parameter determined both at the beginning and end of the period.&#xD;
61 patients ended the period of 7 weeks of placebo treatment (A group + B group) but only 50 have this parameter determined both at the beggining and at the end of the period.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>7-week subcutaneous liraglutide treatment once daily&#xD;
liraglutide: 7-week subcutaneous liraglutide once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>7-week subcutaneous placebo treatment once daily.&#xD;
placebo: 7-week subcutaneous placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Changes from baseline on measurements of respiratory function defined by forced expiratory volume in 1 second (FEV1).&#xD;
Mean difference between 7 weeks after treatment visit and baseline visit is registered.</description>
          <population>59 patients ended the period of 7 weeks of liraglutide treatment (A group + B group) but only 50 have this parameter determined both at the beginning and end of the period.&#xD;
61 patients ended the period of 7 weeks of placebo treatment (A group + B group) but only 50 have this parameter determined both at the beggining and at the end of the period.</population>
          <units>% (FEV1)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="0.0" upper_limit="8.3"/>
                    <measurement group_id="O2" value="4.3" lower_limit="0.1" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline on Measurements of Respiratory Function Defined by Forced Vital Capacity (FVC)</title>
        <description>Changes from baseline on measurements of respiratory function defined by forced vital capacity (FVC).&#xD;
Mean difference between 7 weeks after treatment visit and baseline visit is registered.</description>
        <time_frame>7 weeks</time_frame>
        <population>59 patients ended the period of 7 weeks of liraglutide treatment (A group + B group) but only 50 have this parameter determined both at the beginning and end of the period.&#xD;
61 patients ended the period of 7 weeks of placebo treatment (A group + B group) but only 50 have this parameter determined both at the beginning and end of the period.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>7-week subcutaneous liraglutide treatment once daily&#xD;
liraglutide: 7-week subcutaneous liraglutide once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>7-week subcutaneous placebo treatment once daily.&#xD;
placebo: 7-week subcutaneous placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline on Measurements of Respiratory Function Defined by Forced Vital Capacity (FVC)</title>
          <description>Changes from baseline on measurements of respiratory function defined by forced vital capacity (FVC).&#xD;
Mean difference between 7 weeks after treatment visit and baseline visit is registered.</description>
          <population>59 patients ended the period of 7 weeks of liraglutide treatment (A group + B group) but only 50 have this parameter determined both at the beginning and end of the period.&#xD;
61 patients ended the period of 7 weeks of placebo treatment (A group + B group) but only 50 have this parameter determined both at the beginning and end of the period.</population>
          <units>% (FVC)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="2.1" upper_limit="8.7"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-2.5" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Serum Levels of Surfactant A and D Protein</title>
        <description>Changes from baseline in serum levels of surfactant A and D protein. Values for surfactant A or D protein after 7 treatment weeks (liraglutide or placebo) are registered.</description>
        <time_frame>7 weeks</time_frame>
        <population>59 patients ended the period of 7 weeks of liraglutide treatment (A group + B group) but only 48 have this parameter determined both at the beginning and end of the period.&#xD;
61 patients ended the period of 7 weeks of placebo treatment (A group + B group) but only 48 have this parameter determined both at the beginning and end of the period.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>7-week subcutaneous liraglutide treatment once daily&#xD;
liraglutide: 7-week subcutaneous liraglutide once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>7-week subcutaneous placebo treatment once daily.&#xD;
placebo: 7-week subcutaneous placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Serum Levels of Surfactant A and D Protein</title>
          <description>Changes from baseline in serum levels of surfactant A and D protein. Values for surfactant A or D protein after 7 treatment weeks (liraglutide or placebo) are registered.</description>
          <population>59 patients ended the period of 7 weeks of liraglutide treatment (A group + B group) but only 48 have this parameter determined both at the beginning and end of the period.&#xD;
61 patients ended the period of 7 weeks of placebo treatment (A group + B group) but only 48 have this parameter determined both at the beginning and end of the period.</population>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="30.8" upper_limit="44.5"/>
                    <measurement group_id="O2" value="41.3" lower_limit="21.5" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169.6" lower_limit="108.1" upper_limit="233.6"/>
                    <measurement group_id="O2" value="201.5" lower_limit="115.3" upper_limit="284.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline on Measurements of Respiratory Function Defined by Maximum Mid-expiratory Flow (FEF25-75)</title>
        <description>Changes from baseline on measurements of respiratory function defined by Maximum mid-expiratory flow (FEF25-75).&#xD;
Mean difference between 7 weeks after treatment visit and baseline visit is registered.</description>
        <time_frame>7 weeks</time_frame>
        <population>59 patients ended the period of 7 weeks of liraglutide treatment (A group + B group) but only 46 have this parameter determined both at the beginning and end of the period.&#xD;
61 patients ended the period of 7 weeks of placebo treatment (A group + B group) but only 46 have this parameter determined both at the beginning and end of the period.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>7-week subcutaneous liraglutide treatment once daily&#xD;
liraglutide: 7-week subcutaneous liraglutide once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>7-week subcutaneous placebo treatment once daily.&#xD;
placebo: 7-week subcutaneous placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline on Measurements of Respiratory Function Defined by Maximum Mid-expiratory Flow (FEF25-75)</title>
          <description>Changes from baseline on measurements of respiratory function defined by Maximum mid-expiratory flow (FEF25-75).&#xD;
Mean difference between 7 weeks after treatment visit and baseline visit is registered.</description>
          <population>59 patients ended the period of 7 weeks of liraglutide treatment (A group + B group) but only 46 have this parameter determined both at the beginning and end of the period.&#xD;
61 patients ended the period of 7 weeks of placebo treatment (A group + B group) but only 46 have this parameter determined both at the beginning and end of the period.</population>
          <units>% (FEF25-75)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="-4.1" upper_limit="20.1"/>
                    <measurement group_id="O2" value="12.5" lower_limit="2.2" upper_limit="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second/Forced Vital Capacity (FEV1/FVC)</title>
        <description>Changes from baseline on measurements of respiratory function defined by forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC).&#xD;
Mean difference between 7 weeks after treatment visit and baseline visit is registered.</description>
        <time_frame>7 weeks</time_frame>
        <population>59 patients ended the period of 7 weeks of liraglutide treatment (A group + B group) but only 50 have this parameter determined both at the beginning and end of the period.&#xD;
61 patients ended the period of 7 weeks of placebo treatment (A group + B group) but only 50 have this parameter determined both at the beginning and end of the period.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>7-week subcutaneous liraglutide treatment once daily&#xD;
liraglutide: 7-week subcutaneous liraglutide once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>7-week subcutaneous placebo treatment once daily.&#xD;
placebo: 7-week subcutaneous placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second/Forced Vital Capacity (FEV1/FVC)</title>
          <description>Changes from baseline on measurements of respiratory function defined by forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC).&#xD;
Mean difference between 7 weeks after treatment visit and baseline visit is registered.</description>
          <population>59 patients ended the period of 7 weeks of liraglutide treatment (A group + B group) but only 50 have this parameter determined both at the beginning and end of the period.&#xD;
61 patients ended the period of 7 weeks of placebo treatment (A group + B group) but only 50 have this parameter determined both at the beginning and end of the period.</population>
          <units>% (FEV1/FVC)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-5.1" upper_limit="0.9"/>
                    <measurement group_id="O2" value="1.7" lower_limit="-0.8" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline on Measurements of Respiratory Function Defined by Residual Volume (RV)</title>
        <description>Changes from baseline on measurements of respiratory function defined by residual volume (RV).</description>
        <time_frame>7 weeks</time_frame>
        <population>59 patients ended the period of 7 weeks of liraglutide treatment (A group + B group) but only 12 have this parameter determined both at the beginning and end of the period.&#xD;
61 patients ended the period of 7 weeks of placebo treatment (A group + B group) but only 12 have this parameter determined both at the beginning and end of the period.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>7-week subcutaneous liraglutide treatment once daily&#xD;
liraglutide: 7-week subcutaneous liraglutide once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>7-week subcutaneous placebo treatment once daily.&#xD;
placebo: 7-week subcutaneous placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline on Measurements of Respiratory Function Defined by Residual Volume (RV)</title>
          <description>Changes from baseline on measurements of respiratory function defined by residual volume (RV).</description>
          <population>59 patients ended the period of 7 weeks of liraglutide treatment (A group + B group) but only 12 have this parameter determined both at the beginning and end of the period.&#xD;
61 patients ended the period of 7 weeks of placebo treatment (A group + B group) but only 12 have this parameter determined both at the beginning and end of the period.</population>
          <units>% (RV)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="-17.5" upper_limit="24.1"/>
                    <measurement group_id="O2" value="-1.1" lower_limit="-25.4" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline on Measurements of Respiratory Function Defined by Total Lung Capacity (TLC)</title>
        <description>Changes from baseline on measurements of respiratory function defined by Total lung capacity (TLC).</description>
        <time_frame>7 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>7-week subcutaneous liraglutide treatment once daily&#xD;
liraglutide: 7-week subcutaneous liraglutide once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>7-week subcutaneous placebo treatment once daily.&#xD;
placebo: 7-week subcutaneous placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline on Measurements of Respiratory Function Defined by Total Lung Capacity (TLC)</title>
          <description>Changes from baseline on measurements of respiratory function defined by Total lung capacity (TLC).</description>
          <units>% (TLCO)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-11.9" upper_limit="6.6"/>
                    <measurement group_id="O2" value="-3.1" lower_limit="-9.5" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline on Measurements of Respiratory Function Defined by Residual Functional Capacity (RFC)</title>
        <description>Changes from baseline on measurements of respiratory function defined by Residual functional capacity (RFC) are registered.&#xD;
However, this parameter was not determined in patients due to an error in the programm used.</description>
        <time_frame>7 weeks</time_frame>
        <population>This parameter was not determined in patients due to an error in the programm used.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>7-week subcutaneous liraglutide treatment once daily&#xD;
liraglutide: 7-week subcutaneous liraglutide once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>7-week subcutaneous placebo treatment once daily.&#xD;
placebo: 7-week subcutaneous placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline on Measurements of Respiratory Function Defined by Residual Functional Capacity (RFC)</title>
          <description>Changes from baseline on measurements of respiratory function defined by Residual functional capacity (RFC) are registered.&#xD;
However, this parameter was not determined in patients due to an error in the programm used.</description>
          <population>This parameter was not determined in patients due to an error in the programm used.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 weeks of treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Liraglutide</title>
          <description>7-week subcutaneous liraglutide treatment once daily&#xD;
liraglutide: 7-week subcutaneous liraglutide once daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>7-week subcutaneous placebo treatment once daily.&#xD;
placebo: 7-week subcutaneous placebo once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, family and genetic disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Traumatic injuries, poisonings and complications of therapeutic procedures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anna Royo</name_or_title>
      <organization>Dynamic Science S.L</organization>
      <phone>+34680603119</phone>
      <email>a.royo@dynasolutions.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

